Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIVER: Nalbuphine ER in Refractory Chronic Cough
NCT05962151Phase 2Completed
- Sponsor
- Trevi Therapeutics
- Start
- Nov 2023
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nalbuphine in refractory chronic cough (RCC) (2 arms), sponsored by Trevi Therapeutics. Primary endpoint: Relative Change From Baseline in 24-hour Cough Frequency at 21 days. Started Nov 2023; status: completed.
02
Drugs
nalbuphine
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT05962151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962151.